118 related articles for article (PubMed ID: 3756934)
21. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics of cisplatin and the effect of sodium thiosulfate].
Hayata S; Hitoshi T; Kiyokawa K; Esaki S; Mihashi S; Hirano M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2356-61. PubMed ID: 6541891
[TBL] [Abstract][Full Text] [Related]
23. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik PH
Cancer Clin Trials; 1980; 3(1):23-7. PubMed ID: 7190082
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
25. Potential effects of edema on the pharmacokinetics of platinum in patients treated with cis-dichlorodiammine platinum (II).
Buice RG; Soloway MS
Res Commun Chem Pathol Pharmacol; 1980 Dec; 30(3):447-57. PubMed ID: 7196063
[TBL] [Abstract][Full Text] [Related]
26. Prevention of cisplatin-induced nephrotoxicosis in dogs, using hypertonic saline solution as the vehicle of administration.
Forrester SD; Fallin EA; Saunders GK; Kenny JE
Am J Vet Res; 1993 Dec; 54(12):2175-8. PubMed ID: 8116956
[TBL] [Abstract][Full Text] [Related]
27. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
Guo JH; Song ST; Xu ZL
Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
[TBL] [Abstract][Full Text] [Related]
28. [Study on urinary gamma-GTP activities as an indicator of cis-diamminedichloride platinum nephrotoxicity].
Takahashi T; Yoshida K; Nakame Y; Saitoh H
Hinyokika Kiyo; 1986 Jun; 32(6):789-94. PubMed ID: 2876605
[TBL] [Abstract][Full Text] [Related]
29. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
30. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
31. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.
Osman NM; Copley MP; Litterst CL
Cancer Treat Rep; 1984; 68(7-8):999-1004. PubMed ID: 6540145
[TBL] [Abstract][Full Text] [Related]
32. [Studies on the mechanisms of renal damages induced by nephrotoxic compounds].
Yamada T
Nihon Hoigaku Zasshi; 1995 Dec; 49(6):447-57. PubMed ID: 8583688
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
34. Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
Abe S; Tokizaki T; Miki Y; Tateishi A; Ogawa K; Nakano H; Matsushita T
Cancer Chemother Pharmacol; 2005 Jul; 56(1):55-62. PubMed ID: 15791455
[TBL] [Abstract][Full Text] [Related]
35. [Superselective intra-arterial infusion chemotherapy of high-dose cisplatin for advanced paranasal sinus carcinomas].
Yokoyama J; Shiga K; Saijo S; Matumoto K; Ogawa Y
Gan To Kagaku Ryoho; 1999 Jun; 26(7):967-73. PubMed ID: 10396325
[TBL] [Abstract][Full Text] [Related]
36. Dose optimization of gallium chloride, orally administered, in combination with platinum compounds.
Collery P; Millart H; Kleisbauer JP; Paillotin D; Robinet G; Durand A; Claeyssens S; Legendre JM; Leroy A; Rousseau A
Anticancer Res; 1994; 14(6A):2299-306. PubMed ID: 7825963
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of renal excretion of cisdichlorodiamine platinum.
Caterson R; Etheredge S; Snitch P; Duggin G
Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):255-64. PubMed ID: 6685336
[TBL] [Abstract][Full Text] [Related]
38. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1989; 23(1):37-40. PubMed ID: 2909288
[TBL] [Abstract][Full Text] [Related]
40. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
Kondo Y; Himeno S; Satoh M; Naganuma A; Nishimura T; Imura N
Cancer Chemother Pharmacol; 2004 Jan; 53(1):33-8. PubMed ID: 14530870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
